Basic Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2021; 27(15): 1595-1615
Published online Apr 21, 2021. doi: 10.3748/wjg.v27.i15.1595
Abelson interactor 1 splice isoform-L plays an anti-oncogenic role in colorectal carcinoma through interactions with WAVE2 and full-length Abelson interactor 1
Kun Li, Yi-Fan Peng, Jing-Zhu Guo, Mei Li, Yu Zhang, Jing-Yi Chen, Ting-Ru Lin, Xin Yu, Wei-Dong Yu
Kun Li, Mei Li, Ting-Ru Lin, Department of Central Laboratory and Institute of Clinical Molecular Biology, Peking University People’s Hospital, Beijing 100044, China
Kun Li, Yu Zhang, Jing-Yi Chen, Ting-Ru Lin, Department of Gastroenterology, Peking University People’s Hospital, Peking University, Beijing 100044, China
Yi-Fan Peng, Gastrointestinal Cancer Center, Unit III, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China
Jing-Zhu Guo, Department of Pediatrics, Peking University People’s Hospital, Beijing 100044, China
Yu Zhang, Jing-Yi Chen, Wei-Dong Yu, Department of Central Laboratory and Institute of Clinical Molecular Biology, Peking University People's Hospital, Beijing 100044, China
Xin Yu, Department of Hepatobiliary Surgery, Peking University People’s Hospital, Beijing 100044, China
Author contributions: Li K, Peng YF, and Guo JZ contributed equally to this work and performed the majority of experiments; Li M, Zhang Y, Chen JY, Lin TR, and Yu X performed minor experiments, provided vital reagents, and were also involved in revising the manuscript; Peng YF and Yu WD designed the study, wrote the manuscript, and provided financial support; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 30872923 and No. 81672853; and Peking University People’s Hospital Scientific Research Development Found, No. RDH2020-11.
Institutional review board statement: The study was reviewed and approved by the Peking University People’s Hospital Institutional Review Board (No. 2020-11).
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Wei-Dong Yu, PhD, Professor, Department of Central Laboratory and Institute of Clinical Molecular Biology, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China. weidongyu@bjmu.edu.cn
Received: January 21, 2021
Peer-review started: January 21, 2021
First decision: February 9, 2021
Revised: February 17, 2021
Accepted: March 13, 2021
Article in press: March 13, 2021
Published online: April 21, 2021
Processing time: 82 Days and 21.1 Hours
Abstract
BACKGROUND

Expression of the full-length isoform of Abelson interactor 1 (ABI1), ABI1-p65, is increased in colorectal carcinoma (CRC) and is thought to be involved in one or more steps leading to tumor progression or metastasis. The ABI1 splice isoform-L (ABI1-SiL) has conserved WAVE2-binding and SH3 domains, lacks the homeo-domain homologous region, and is missing the majority of PxxP- and Pro-rich domains found in full-length ABI1-p65. Thus, ABI1-SiL domain structure suggests that the protein may regulate CRC cell morphology, adhesion, migration, and metastasis via interactions with the WAVE2 complex pathway.

AIM

To investigate the potential role and underlying mechanisms associated with ABI1-SiL-mediated regulation of CRC.

METHODS

ABI1-SiL mRNA expression in CC tissue and cell lines was measured using both qualitative reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time quantitative RT-PCR. A stably ABI1-SiL overexpressing SW480 cell model was constructed using Lipofectamine 2000, and cells selected with G418. Image J software, CCK8, and transwell assays were used to investigate SW480 cell surface area, proliferation, migration, and invasion. Immunoprecipitation, Western blot, and co-localization assays were performed to explore intermolecular interactions between ABI1-SiL, WAVE2, and ABI1-p65 proteins.

RESULTS

ABI1-SiL was expressed in normal colon tissue and was significantly decreased in CRC cell lines and tissues. Overexpression of ABI1-SiL in SW480 cells significantly increased the cell surface area and inhibited the adhesive and migration properties of the cells, but did not alter their invasive capacity. Similar to ABI1-p65, ABI1-SiL still binds WAVE2, and the ABI1-p65 isoform in SW480 cells. Furthermore, co-localization assays confirmed these intermolecular interactions.

CONCLUSION

These results support a model in which ABI1-SiL plays an anti-oncogenic role by competitively binding to WAVE2 and directly interacting with phosphorylated and non-phosphorylated ABI1-p65, functioning as a dominant-negative form of ABI1-p65.

Keywords: Colon cancer; Abelson interactor 1 isoform-L; Cell adhesion; Cell migration; WAVE2

Core Tip: The purpose of this study was to investigate the role and mechanism of Abelson interactor 1 splice isoform-L (ABI1-SiL) in the metastatic behavior of colorectal carcinoma cells. Our results showed that ABI1-SiL played a key role in cell surface area, adhesion, and migration, but not in proliferation and apoptosis in SW480 cells. ABI1-SiL may have anti-oncogenic roles by competitively binding to WAVE2, and directly interacting with phosphorylated and non-phosphorylated ABI1-p65, functioning as a dominant-negative molecule towards ABI1-p65.